Gilead Of U.S. Seeks Indian Partnerships, Licenses For Biotech Drugs
This article was originally published in PharmAsia News
Executive Summary
U.S. biotech Gilead Science is ready to outsource manufacturing and research in India and seeks partnerships, an executive says. The firm also seeks to license more of its drugs in India, including its Viread HIV/AIDS drug at roughly $210 a year. Gilead already has ties to India's Piramal Healthcare for marketing the branded and generic versions of the drug at the same time. Several other Indian companies have been granted licenses to sell Viread at a price of their choosing. (Click here for more - a subscription may be required